ライフサイエンスコーパス: coronary angioplasty

1 atients undergoing percutaneous transluminal coronary angioplasty).

2 al delivery of cytochalasin B at the site of coronary angioplasty.

3 s in patients with previous restenosis after coronary angioplasty.

4 Twenty-three swine underwent multivessel coronary angioplasty.

5 d platelet activation and interaction during coronary angioplasty.

6 may contribute to an improved outcome after coronary angioplasty.

7 latelet adherence to leukocytes occurs after coronary angioplasty.

8 gnificantly higher acute costs compared with coronary angioplasty.

9 ing transitory MIS in the setting of planned coronary angioplasty.

10 (CABG) surgery and percutaneous transluminal coronary angioplasty.

11 s in patients with previous restenosis after coronary angioplasty.

12 ss graft (CABG) or percutaneous transluminal coronary angioplasty.

13 30 days among patients undergoing high-risk coronary angioplasty.

14 randomized to tirofiban or placebo following coronary angioplasty.

15 cell interactions may affect the outcome of coronary angioplasty.

16 ajor adverse cardiac events after successful coronary angioplasty.

17 lockers can reduce ischemic complications of coronary angioplasty.

18 receive either bivalirudin or heparin during coronary angioplasty.

19 ter outcomes for elderly patients undergoing coronary angioplasty.

20 ly (within 1 week) and late (>6 weeks) after coronary angioplasty.

21 cation that limits the long-term efficacy of coronary angioplasty.

22 variably associated with complications after coronary angioplasty.

23 ffects in animal models and in humans during coronary angioplasty.

24 al coronary branch occlusion during elective coronary angioplasty.

25 FR <0.75 underwent percutaneous transluminal coronary angioplasty.

26 d optimized might be a beneficial adjunct to coronary angioplasty.

27 verall adverse late outcome after successful coronary angioplasty.

28 bo sources in patients with restenosis after coronary angioplasty.

29 s graft surgery or percutaneous transluminal coronary angioplasty.

30 t occurs following percutaneous transluminal coronary angioplasty.

31 the short-term and the long-term outcomes of coronary angioplasty.

32 rrelated with the prevalence of percutaneous coronary angioplasty (-0.717; -0.787) and coronary arter

33 ngiography (19.2% versus 15.2%, P=.0001) and coronary angioplasty (11.6% versus 8.2%, P<.0001).

34 s was $3,268 higher than for those receiving coronary angioplasty ($14,802 vs. $11,534, p < 0.001).

35 patients, with the largest effect seen with coronary angioplasty (15% versus 20% for heparin, P=.04)

36 tion (57% versus 63% for heparin, P=.04) and coronary angioplasty (18% versus 22%, P=.08).

37 y angiography (67.1% versus 39.3%, P<.0001), coronary angioplasty (32.5% versus 13.2%, P<.0001), or c

38 ; reperfusion, using thrombolytic therapy or coronary angioplasty (67.2% [59.8%-75.1%]); prescription

39 s that occur after percutaneous transluminal coronary angioplasty, a widespread treatment for coronar

40 infarction, after percutaneous transluminal coronary angioplasty, after coronary artery bypass graft

41 better quality of life for three years than coronary angioplasty, after the initial morbidity caused

42 as clinical benefits beyond those of primary coronary angioplasty alone.

43 s have not shown convincing superiority over coronary angioplasty alone.

44 % (64% for balloon percutaneous transluminal coronary angioplasty and 33% for coronary stenting [P=0.

45 cations, physicians from hospitals providing coronary angioplasty and bypass surgery rated angiograph

46 ip between the time to treatment with direct coronary angioplasty and clinical outcome.

47 s measured by the prevalence of percutaneous coronary angioplasty and coronary artery bypass graft su

48 n procedure (i.e., percutaneous transluminal coronary angioplasty and coronary artery bypass graft su

49 Patients undergoing percutaneous coronary angioplasty and coronary artery bypass graft we

50 Before coronary angioplasty and heart surgery, these preconditi

51 f restenosis after percutaneous transluminal coronary angioplasty and in the progression of atheroscl

52 ive in reducing ischemic complications after coronary angioplasty and in unstable angina, making this

53 iators occur after percutaneous transluminal coronary angioplasty and may play a role in restenosis.

54 0% to 50% of vascular interventions, such as coronary angioplasty and peripheral vein grafting.

55 Currently, more than one million coronary angioplasty and stent implantation procedures a

56 risk in a cohort of 284 patients undergoing coronary angioplasty and stent placement (rs350099: TT v

57 ral angiography and 20 patients treated with coronary angioplasty and stent placement.

58 However, its effects after coronary angioplasty and the cellular mechanisms involve

59 s an important mechanism of restenosis after coronary angioplasty and the primary mechanism of resten

60 inistered by local delivery after successful coronary angioplasty and warrants further study of its e

61 scularization with percutaneous transluminal coronary angioplasty and/or coronary artery bypass graft

62 site facilities for cardiac catheterization, coronary angioplasty, and bypass surgery (similarly equi

63 mpared six and 12 month cumulative costs for coronary angioplasty- and stent-treated cohorts.

64 graft surgery and percutaneous transluminal coronary angioplasty are directed at more severe coronar

65 ypass grafting and percutaneous transluminal coronary angioplasty are now well established methods of

66 utcomes for patients undergoing percutaneous coronary angioplasty at 30 days and at 6 months.

67 limited the clinical outcomes of multivessel coronary angioplasty before stents were available to imp

68 Percutaneous coronary angioplasty can be performed with low mortality

69 tionship for coronary artery bypass surgery, coronary angioplasty, carotid endarterectomy, other canc

70 y bypass grafting, percutaneous transluminal coronary angioplasty, carotid endarterectomy, reduction

71 rumentation with a percutaneous transluminal coronary angioplasty catheter advanced to the mid-left a

72 Restoration of disposable coronary angioplasty catheters using a highly controlled

73 nfatal MI, stroke, percutaneous transluminal coronary angioplasty, coronary artery bypass graft or de

74 cardiovascular event (myocardial infarction, coronary angioplasty, coronary artery bypass graft surge

75 ardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft surge

76 tion (MI), stroke, percutaneous transluminal coronary angioplasty, coronary artery bypass graft, or d

77 ardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, i

78 tegrins (abciximab; c7E3 Fab) at the time of coronary angioplasty decreases the need for repeat revas

79 rocedures included percutaneous transluminal coronary angioplasty, directional or rotational atherect

80 to short-term cognitive dysfunction, whereas coronary angioplasty does not.

81 graft surgery and percutaneous transluminal coronary angioplasty) during six month follow-up.

82 anisms and clinical results of excimer laser coronary angioplasty (ELCA) versus rotational atherectom

83 rvention: group 1 (percutaneous transluminal coronary angioplasty era), group 2 (early stent era), gr

84 an oral sirolimus-loading dose of 6 mg after coronary angioplasty, followed by 2 mg/d for 4 weeks.

85 1+/-10 years) who were on a waiting list for coronary angioplasty for a mean time of 4.8+/-2.4 months

86 outcome of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (MI

87 dy was to determine predictors of successful coronary angioplasty for acute myocardial infarction (MI

88 tcome in diabetic patients undergoing direct coronary angioplasty for acute myocardial infarction.

89 mortality among diabetic patients undergoing coronary angioplasty for acute myocardial infarction.

90 n while undergoing percutaneous transluminal coronary angioplasty for single-vessel coronary artery d

91 ere measured in 20 patients before and after coronary angioplasty for stable angina at three sampling

92 mplications in high risk patients undergoing coronary angioplasty for thrombus-containing lesions det

93 schemic complications in patients undergoing coronary angioplasty for thrombus-containing lesions det

94 atients undergoing percutaneous transluminal coronary angioplasty from the period 1980 through 1989 t

95 Coronary angioplasty has a lower five-year cost than byp

96 Coronary angioplasty has numerous shortcomings.

97 us coronary bypass surgery, as compared with coronary angioplasty, has a highly favorable influence o

98 s studies have shown that women treated with coronary angioplasty have a higher incidence of procedur

99 Patients who undergo coronary angioplasty have a shorter convalescence than t

100 ass surgery, coronary artery bypass surgery, coronary angioplasty, heart transplantation, pediatric c

101 herapy, was associated with lower mortality (coronary angioplasty: HR 0.51, 95% CI 0.32 to 0.81; coro

102 mab bolus with infusion given at the time of coronary angioplasty improves outcomes as long as 3 year

103 not improve after percutaneous transluminal coronary angioplasty in > or = 50% of patients, postulat

104 f physicians and 25% of hospitals performing coronary angioplasty in 1992 were unlikely to have met t

105 utcomes after coronary bypass surgery versus coronary angioplasty in 525 patients with pharmacologica

106 ents who underwent percutaneous transluminal coronary angioplasty in BARI.

107 fficacy of primary percutaneous transluminal coronary angioplasty in patients with acute myocardial i

108 oplasty and reduce rates of restenosis after coronary angioplasty in selected patients.

109 ine both the time required to perform direct coronary angioplasty in the Global Use of Strategies to

110 is similar after coronary bypass surgery and coronary angioplasty in the majority of patients.

111 lloon angioplasty (percutaneous transluminal coronary angioplasty) in contemporary clinical practice.

112 disease: repeated balloon inflations before coronary angioplasty induce preconditioning-like effects

113 Restenosis after coronary angioplasty is a major limitation of an otherwi

114 monstrated 6 months after medical therapy or coronary angioplasty is a valuable prognostic marker in

115 Coronary angioplasty is an alternative revascularization

116 Percutaneous transluminal coronary angioplasty is an alternative to CABG for patie

117 on during elective percutaneous transluminal coronary angioplasty is associated with myocardial ische

118 clinical trials have shown that multivessel coronary angioplasty is feasible and provides similar lo

119 clusive disease by percutaneous transluminal coronary angioplasty is hampered by maladaptive wound he

120 Prophylactic percutaneous transluminal coronary angioplasty is one revascularization strategy e

121 Although the frequency of restenosis after coronary angioplasty is reduced by stenting, when resten

122 Whereas it is arguable whether coronary angioplasty is superior to thrombolytic therapy

123 grafts) underwent percutaneous transluminal coronary angioplasty, laser ablation, rotational atherec

124 ronaries underwent percutaneous transluminal coronary angioplasty, laser angioplasty, rotational athe

125 bypass grafting or percutaneous transluminal coronary angioplasty, <60 days after nuclear testing, th

126 undergo noncardiac surgery within 90days of coronary angioplasty may be at increased risk for postop

127 Other therapies, such as primary coronary angioplasty, may be preferable in patients with

128 cates was analyzed in 2,127 patients who had coronary angioplasty (mean age 57.6 years) without acute

129 Percutaneous transluminal coronary angioplasty (n = 10) was unsuccessful in two pa

130 received either coronary stent (n = 384) or coronary angioplasty (n = 159) and met eligibility crite

131 ndomized comparison of a strategy of initial coronary angioplasty (n = 198) or coronary bypass surger

132 Patients randomized to direct coronary angioplasty (n=565) were divided into groups ba

133 revascularization (percutaneous transluminal coronary angioplasty, n=20; coronary artery bypass surge

134 nd Blood Institute Percutaneous Transluminal Coronary Angioplasty (NHLBI PTCA) Registry.

135 Major complications of coronary angioplasty occur in 4% to 9% of patients.

136 Since the first coronary angioplasty on Sept 16, 1977, the field of perc

137 or the need for coronary revascularization (coronary angioplasty or bypass surgery).

138 ography (within 24 hours of shock onset) and coronary angioplasty or bypass surgery, if appropriate,

139 atients who underwent revascularization with coronary angioplasty or coronary artery bypass graft sur

140 atheterization and percutaneous transluminal coronary angioplasty or coronary artery bypass graft sur

141 revascularization (percutaneous transluminal coronary angioplasty or coronary artery bypass graft).

142 previous revascularization with percutaneous coronary angioplasty or coronary artery bypass grafting.

143 atients undergoing percutaneous transluminal coronary angioplasty or coronary stenting initially and

144 ications among patients undergoing high-risk coronary angioplasty or directional atherectomy but incr

145 iovascular events at both 2 and 7 days after coronary angioplasty or directional coronary atherectomy

146 ndom assignment to percutaneous transluminal coronary angioplasty or medical therapy in the Angioplas

147 yocardial infarction, bypass surgery, repeat coronary angioplasty or severe angina at 1 year was 66.7

148 erence in long-term results for freedom from coronary angioplasty or stenting, renal dysfunction, dia

149 , or angina, coronary artery bypass surgery, coronary angioplasty, or abnormal coronary angiographic

150 y bypass grafting, percutaneous transluminal coronary angioplasty, or angiographic evidence of signif

151 c catheterization, percutaneous transluminal coronary angioplasty, or coronary artery bypass grafting

152 (myocardial infarction, angina, percutaneous coronary angioplasty, or coronary artery bypass surgery)

153 artery bypass graft procedure, percutaneous coronary angioplasty, or CVD death) occurred during a me

154 y bypass grafting, percutaneous transluminal coronary angioplasty, or other revascularization), strok

155 , 95% confidence interval [CI] 0.24 to 0.58; coronary angioplasty: OR 0.60, 95% CI 0.25 to 1.49; coro

156 Although refinements have occurred in coronary angioplasty over the past decade, little is kno

157 y bypass graft and percutaneous transluminal coronary angioplasty (p<0.001 and p=0.005, respectively)

158 5% vs. 11.5% after percutaneous transluminal coronary angioplasty; p < 0.01).

159 cancer resection, cardiac valve replacement, coronary angioplasty, pancreatic cancer resection, and t

160 vascularization (9% vs. 26%, p = 0.001) than coronary angioplasty patients within six months of the p

161 s with multivessel percutaneous transluminal coronary angioplasty, patients who undergo multivessel s

162 Grafting' (CABG), 'percutaneous transluminal coronary angioplasty' (PCTA) and 'Other Coronary Heart D

163 The benefits of primary coronary angioplasty persisted when stratified by hospit

164 gn have made stent implantation the standard coronary angioplasty procedure.

165 -2.29), coronary artery bypass graft surgery/coronary angioplasty procedure/stent (1.35; 1.08-1.69),

166 nverse relation exists between the number of coronary angioplasty procedures performed by physicians

167 hat physicians who perform larger numbers of coronary angioplasty procedures will have better outcome

168 atheterization and percutaneous transluminal coronary angioplasty (PTCA) (ad hoc) in comparison with

169 are the outcome of percutaneous transluminal coronary angioplasty (PTCA) (n = 834) and coronary arter

170 in one branch and percutaneous transluminal coronary angioplasty (PTCA) (with or without atherectomy

171 ombolysis, primary percutaneous transluminal coronary angioplasty (PTCA) after acute myocardial infar

172 inical features of percutaneous transluminal coronary angioplasty (PTCA) after failed thrombolysis fo

173 ,154 patients with percutaneous transluminal coronary angioplasty (PTCA) alone, 876 patients with cor

174 fully managed with percutaneous transluminal coronary angioplasty (PTCA) alone.

175 obtained from 100 percutaneous transluminal coronary angioplasty (PTCA) and 75 cardiac surgical pati

176 ft surgery (CABG), percutaneous transluminal coronary angioplasty (PTCA) and cardiac catheterization

177 rm consequences of percutaneous transluminal coronary angioplasty (PTCA) and continued medical treatm

178 cularization using percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass (

179 The impact of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass g

180 etes after initial percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass g

181 Percutaneous transluminal coronary angioplasty (PTCA) and coronary-artery bypass g

182 appropriateness of percutaneous transluminal coronary angioplasty (PTCA) and coronary-artery bypass g

183 Institute (NHLBI) Percutaneous Transluminal Coronary Angioplasty (PTCA) and New Approaches to Corona

184 ontaneously before percutaneous transluminal coronary angioplasty (PTCA) and the likelihood of an isc

185 complication after percutaneous transluminal coronary angioplasty (PTCA) and to determine its clinica

186 risk of performing percutaneous transluminal coronary angioplasty (PTCA) at the time of diagnostic ca

187 gated the reuse of percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, restored

188 hospitals without percutaneous transluminal coronary angioplasty (PTCA) capability.

189 rfusion by primary percutaneous transluminal coronary angioplasty (PTCA) compared with thrombolytic t

190 bolytic therapy or percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarct

191 udy comparing intensive medical therapy with coronary angioplasty (PTCA) for suppression of myocardia

192 urgery (CABG) with percutaneous transluminal coronary angioplasty (PTCA) for the treatment of coronar

193 Percutaneous transluminal coronary angioplasty (PTCA) has become the dominant trea

194 The term rescue percutaneous transluminal coronary angioplasty (PTCA) has been introduced to descr

195 tion after primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarcti

196 c therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarcti

197 rfusion by primary percutaneous transluminal coronary angioplasty (PTCA) in AMI include in-hospital r

198 s graft (CABG) and percutaneous transluminal coronary angioplasty (PTCA) in high-risk anatomic subset

199 ma formation after percutaneous transluminal coronary angioplasty (PTCA) in porcine coronary arteries

200 rterial wall after percutaneous transluminal coronary angioplasty (PTCA) induces thrombus formation a

201 Although percutaneous transluminal coronary angioplasty (PTCA) is a highly effective proced

202 surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA) may be different in the pres

203 tudy applied the New York State conventional coronary angioplasty (PTCA) model of clinical outcomes t

204 ls for in-hospital percutaneous transluminal coronary angioplasty (PTCA) mortality on an independent

205 Adjunctive percutaneous transluminal coronary angioplasty (PTCA) of the culprit artery restor

206 le swine underwent percutaneous transluminal coronary angioplasty (PTCA) of the left anterior descend

207 rimary stenting or percutaneous transluminal coronary angioplasty (PTCA) on health-related quality of

208 ho were undergoing percutaneous transluminal coronary angioplasty (PTCA) or CABG at Duke University M

209 ary arteriography, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass gr

210 scularization with percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass gr

211 mmendation was for percutaneous transluminal coronary angioplasty (PTCA) or for coronary artery bypas

212 ed to treatment by percutaneous transluminal coronary angioplasty (PTCA) or medical therapy, compared

213 omes after primary percutaneous transluminal coronary angioplasty (PTCA) or thrombolytic therapy for

214 eath after a first percutaneous transluminal coronary angioplasty (PTCA) procedure, in postmenopausal

215 ween the number of percutaneous transluminal coronary angioplasty (PTCA) procedures performed at hosp

216 nd 1993-1994 NHLBI Percutaneous Transluminal Coronary Angioplasty (PTCA) registries.

217 ith a "stent-like" percutaneous transluminal coronary angioplasty (PTCA) remains unknown.

218 economic impact of percutaneous transluminal coronary angioplasty (PTCA) revascularization salvage st

219 comes of a primary percutaneous transluminal coronary angioplasty (PTCA) strategy.

220 erial injury after percutaneous transluminal coronary angioplasty (PTCA) triggers acute thrombus form

221 laser-facilitated percutaneous transluminal coronary angioplasty (PTCA) versus "stand-alone" PTCA.

222 ndom assignment of percutaneous transluminal coronary angioplasty (PTCA) versus coronary artery bypas

223 A history of percutaneous transluminal coronary angioplasty (PTCA) was present in 35.4% of the

224 n (AMI) undergoing percutaneous transluminal coronary angioplasty (PTCA) with an optimal or "stent-li

225 angina undergoing percutaneous transluminal coronary angioplasty (PTCA) with predicted coronary arte

226 to compare primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy fo

227 rfusion by primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy in

228 s grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), abdominal aortic aneurysm (

229 I), cardiac death, percutaneous transluminal coronary angioplasty (PTCA), and coronary artery bypass

230 c catheterization, percutaneous transluminal coronary angioplasty (PTCA), and coronary artery bypass

231 rpulsation (IABP), percutaneous transluminal coronary angioplasty (PTCA), and coronary bypass graft s

232 20 years, percutaneous transluminal balloon coronary angioplasty (PTCA), bare-metal stents (BMS), an

233 , as compared with percutaneous transluminal coronary angioplasty (PTCA), influences the prognosis in

234 s grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), or minimally invasive coron

235 hesis that primary percutaneous transluminal coronary angioplasty (PTCA), with subsequent discharge f

236 cular events after percutaneous transluminal coronary angioplasty (PTCA).

237 atients undergoing percutaneous transluminal coronary angioplasty (PTCA).

238 f restenosis after percutaneous transluminal coronary angioplasty (PTCA).

239 CABG) but not with percutaneous transluminal coronary angioplasty (PTCA).

240 cal outcomes after percutaneous transluminal coronary angioplasty (PTCA).

241 logical subset for percutaneous transluminal coronary angioplasty (PTCA).

242 omplications after percutaneous transluminal coronary angioplasty (PTCA).

243 r use in high-risk percutaneous transluminal coronary angioplasty (PTCA).

244 rafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA).

245 ry reperfusion via percutaneous transluminal coronary angioplasty (PTCA).

246 d after adjunctive percutaneous transluminal coronary angioplasty (PTCA).

247 s occurring during percutaneous transluminal coronary angioplasty (PTCA).

248 atients undergoing percutaneous transluminal coronary angioplasty (PTCA).

249 y or after primary percutaneous transluminal coronary angioplasty (PTCA).

250 s in humans during percutaneous transluminal coronary angioplasty (PTCA).

251 nting (STENT), and percutaneous transluminal coronary angioplasty (PTCA).

252 ntral to the development of restenosis after coronary angioplasty (PTCA).

253 ntima formation that causes restenosis after coronary angioplasty (PTCA).

254 ndesired effect of percutaneous transluminal coronary angioplasty (PTCA).

255 ABG) compared with percutaneous transluminal coronary angioplasty (PTCA).

256 nd neointima formation limit the efficacy of coronary angioplasty (PTCA).

257 nary arteriography (cath-capable, 25.2%); 3) coronary angioplasty (PTCA-capable, 7.4%); and 4) bypass

258 er, they underwent percutaneous transluminal coronary angioplasty (PTCA; three 2-minute balloon infla

259 eath, nonfatal MI, percutaneous transluminal coronary angioplasty [PTCA] or coronary artery bypass gr

260 grafting [CABG] or percutaneous transluminal coronary angioplasty [PTCA]) and renal transplantation a

261 alloon dilatation (percutaneous transluminal coronary angioplasty [PTCA]) for the treatment of in-ste

262 lloon angioplasty (percutaneous transluminal coronary angioplasty [PTCA]).

263 lloon angioplasty (percutaneous transluminal coronary angioplasty, PTCA) in the treatment of diffuse

264 rial injury (i.e., percutaneous transluminal coronary angioplasty, PTCA) is unknown.

265 Over 400,000 percutaneous transluminal coronary angioplasties (PTCAs) are currently performed a

266 New York's Coronary Angioplasty Registry was used to identify New Y

267 New York's coronary angioplasty registry was used to identify New Y

268 n, cardiac arrest, percutaneous transluminal coronary angioplasty, repeat CABG, and cardiac mortality

269 e analyzed data from the 1995 New York State Coronary Angioplasty Reporting System Registry to determ

270 Surgical and percutaneous transluminal coronary angioplasty revascularization performed before

271 signed 479 patients undergoing single-vessel coronary angioplasty routine stent implantation or initi

272 low-risk patients, percutaneous transluminal coronary angioplasty seems to control angina better than

273 Repetitive platelet accumulation at coronary angioplasty sites caused enhanced neointimal pr

274 inducing repetitive platelet aggregation at coronary angioplasty sites in dogs and measuring subsequ

275 ysis, conventional percutaneous transluminal coronary angioplasty, stenting, glycoprotein IIb/IIIa in

276 d the number of elective cardiac procedures (coronary angioplasty, stenting, or coronary bypass surge

277 likely to undergo percutaneous transluminal coronary angioplasty than other patients, whereas patien

278 disease achieve more symptomatic relief with coronary angioplasty than with medical therapy alone, bu

279 Restenosis is a serious complication of coronary angioplasty that involves the proliferation and

280 ials not involving percutaneous transluminal coronary angioplasty, the pooled effect size was -0.06 (

281 n trials involving percutaneous transluminal coronary angioplasty, the pooled relative risk of resten

282 ay, they underwent percutaneous transluminal coronary angioplasty (three 2-minute balloon inflations

283 IC), Evaluation of Percutaneous Transluminal Coronary Angioplasty to Improve Long-term Outcome of c7E

284 Heparin is administered during coronary angioplasty to prevent closure of the dilated v

285 bypass surgery or percutaneous transluminal coronary angioplasty, transmyocardial revascularization

286 s, including after percutaneous transluminal coronary angioplasty, unstable angina, stress-induced is

287 During coronary angioplasty, venous blood was obtained for flow

288 o determine whether the results of the first Coronary Angioplasty Versus Excisional Atherectomy Trial

289 ients treated with percutaneous transluminal coronary angioplasty versus thrombolysis.

290 Coronary angioplasty was less likely to be performed whe

291 results when PTCA (percutaneous transluminal coronary angioplasty) was performed, complication rates,

292 ults on neointima formation at 4 weeks after coronary angioplasty were compared with the control grou

293 pass grafting, and percutaneous transluminal coronary angioplasty were higher in for-profit health pl

294 Forty patients undergoing successful coronary angioplasty were randomized into four equal gro

295 Twenty-two patients undergoing coronary angioplasty were randomized to an intracoronary

296 total of 2099 high-risk patients undergoing coronary angioplasty were randomized.

297 Randomized trials comparing coronary angioplasty with bypass surgery in patients wit

298 s may undergo medical treatment/observation, coronary angioplasty with stent deployment, or surgical

299 rocedures is performed as single or multiple coronary angioplasty with stenting using either bare met

300 l space would reduce luminal narrowing after coronary angioplasty without affecting systemic hemodyna